Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

88.4K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
88.4K
Sanger Sequencing01:57

Sanger Sequencing

753.8K
DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
753.8K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Barriers And Facilitators To Next-generation Sequencing Use In United States Oncology Settings: A Systematic Review.

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review.

Andrea Ferreira-Gonzalez1, Gilbert Ko2, Nicole Fusco3

  • 1Pathology Department, Virginia Commonwealth University, Richmond, VA 23298-0662, USA.

Future Oncology (London, England)
|September 24, 2024

Related Experiment Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

View abstract on PubMed

Summary
This summary is machine-generated.

Next-generation sequencing (NGS) for solid tumors is underutilized due to complex reimbursement and unclear clinical utility. Improving insurance policies and reimbursement frameworks is crucial for increasing patient access to this vital cancer diagnostic tool.

Area of Science:

  • Oncology
  • Genomics
  • Health Services Research

Background:

  • Next-generation sequencing (NGS) offers significant potential for guiding solid tumor treatment decisions.
  • Despite its benefits, the adoption of NGS in clinical oncology settings remains suboptimal.
  • Identifying barriers and facilitators is essential to improve NGS utilization.

Approach:

  • A systematic review of studies published between 2012 and 2023 was conducted.
  • Literature searches were performed in Embase and MEDLINE databases.
  • Included studies focused on barriers and facilitators of NGS adoption for solid tumors in US oncology settings, excluding hereditary cancer and non-US studies.

Key Points:

  • Complex reimbursement processes and uncertainty regarding clinical utility emerged as primary barriers to NGS adoption.
Keywords:
clinical oncologygenetic testinghigh-throughput sequencingmassive parallel sequencing

Related Experiment Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
  • Inclusion of NGS recommendations in clinical practice guidelines acted as a facilitator.
  • Insurance policies frequently presented more restrictions than guideline recommendations, hindering access.

    • Conclusions:

    • While NGS uptake is growing, significant barriers persist, particularly concerning reimbursement.
    • Revisions to current reimbursement frameworks are necessary to enhance patient access to NGS.
    • The long-term impact of the 2018 National Coverage Determination on NGS access for Medicare beneficiaries with advanced cancer requires further investigation.
    next-generation sequencing
    precision medicine
    qualitative evidence synthesis
    systematic review